Myeloid immunosuppression and immune checkpoints in the tumor microenvironment
Top Cited Papers
- 14 October 2019
- journal article
- review article
- Published by Springer Nature in Cellular & Molecular Immunology
- Vol. 17 (1) , 1-12
Abstract
Tumor-promoting inflammation and the avoidance of immune destruction are hallmarks of cancer. While innate immune cells, such as neutrophils, monocytes, and macrophages, are critical mediators for sterile and nonsterile inflammation, persistent inflammation, such as that which occurs in cancer, is known to disturb normal myelopoiesis. This disturbance leads to the generation of immunosuppressive myeloid cells, such as myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages (TAMs). Due to their potent suppressive activities against effector lymphocytes and their abundance in the tumor microenvironment, immunosuppressive myeloid cells act as a major barrier to cancer immunotherapy. Indeed, various therapeutic approaches directed toward immunosuppressive myeloid cells are actively being tested in preclinical and clinical studies. These include anti-inflammatory agents, therapeutic blockade of the mobilization and survival of myeloid cells, and immunostimulatory adjuvants. More recently, immune checkpoint molecules expressed on tumor-infiltrating myeloid cells have emerged as potential therapeutic targets to redirect these cells to eliminate tumor cells. In this review, we discuss the complex crosstalk between cancer-related inflammation and immunosuppressive myeloid cells and possible therapeutic strategies to harness antitumor immune responses.Keywords
Funding Information
- Department of Health | National Health and Medical Research Council (1078671, 1132519)
- Naito Foundation
This publication has 225 references indexed in Scilit:
- Aspirin and cancer risk: a quantitative review to 2011Annals of Oncology, 2012
- Receptor Tyrosine Kinases and TLR/IL1Rs Unexpectedly Activate Myeloid Cell PI3Kγ, A Single Convergent Point Promoting Tumor Inflammation and ProgressionCancer Cell, 2011
- Paired Immunoglobin-like Receptor-B Regulates the Suppressive Function and Fate of Myeloid-Derived Suppressor CellsImmunity, 2011
- The Role of Uric Acid as an Endogenous Danger Signal in Immunity and InflammationCurrent Rheumatology Reports, 2011
- CD169-Positive Macrophages Dominate Antitumor Immunity by Crosspresenting Dead Cell-Associated AntigensImmunity, 2011
- Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin LymphomaCell, 2010
- CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem CellsCell, 2009
- Cancer-related inflammationNature, 2008
- Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin–cyclophosphamide chemotherapyCancer Immunology, Immunotherapy, 2008
- Identification of Tim4 as a phosphatidylserine receptorNature, 2007